ledipasvir + GS-9451 + ribavirin

This is a **combination regimen** of three direct-acting antiviral agents used in clinical trials for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotype 1. - **Ledipasvir** is an NS5A inhibitor, targeting the HCV NS5A protein critical for viral replication and assembly. - **GS-9451** is a selective HCV NS3 protease inhibitor that inhibits a key viral enzyme required for processing the HCV polyprotein. - **Ribavirin** is a nucleoside analog with broad-spectrum antiviral activity that inhibits viral RNA synthesis and capping. This combination is designed to attack multiple stages of the HCV life cycle, aiming for additive or synergistic antiviral effects and aiming to reduce the emergence of resistance[1][4]. It was evaluated in clinical trials, including combination studies with pegylated interferon, but is not an approved standard-of-care therapy; rather, these drugs have been more widely used in other dual or triple direct-acting antiviral regimens. There is no unique commercial brand name for this specific combination, as it was primarily tested in clinical settings and not marketed as a fixed-dose product.

Other names

ledipasvir + GS-9451 + ribavirinGS-5885 + GS-9451 + RBV